淋巴细胞减少作为早期乳腺癌同侧乳腺肿瘤复发的潜在预测指标
Lymphopenia as a Potential Predictor of Ipsilateral Breast Tumor Recurrence in Early Breast Cancer.
作者信息
Cho Oyeon, Chun Mison, Kim Sang Won, Jung Yong Sik, Yim Hyunee
机构信息
Department of Radiation Oncology, Ajou University School of Medicine, Suwon, Republic of Korea
Department of Radiation Oncology, Konyang University School of Medicine, Daejeon, Republic of Korea.
出版信息
Anticancer Res. 2019 Aug;39(8):4467-4474. doi: 10.21873/anticanres.13620.
BACKGROUND/AIM: The aim of this study was to investigate the association between lymphopenia after breast conserving therapy (BCT) and ipsilateral breast tumor recurrence (IBTR) in early breast cancer (EBC).
PATIENTS AND METHODS
We examined 216 EBC patients treated with partial mastectomy followed by radiotherapy (RT), none of whom received chemotherapy. Absolute lymphocyte counts (ALCs) during the two years after RT were collected from each patient: pretreatment ALC, ALC at 3-5 months (ALC1), ALC at 9-11 months, ALC at 15-17 months, and ALC at 21-23 months.
RESULTS
The 102 patients with ALC1 ≤1,479 cells/μl (defined as lymphopenia) had significantly higher 10-year IBTR rate than the 102 patients with ALC1 >1,479 cells/μl (16.2% vs. 1%, p=0.0034). The multivariate analysis showed that age, resection margins, human epidermal growth factor receptor, and lymphopenia were significant predictors of IBTR.
CONCLUSION
Lymphopenia is a potential predictor for IBTR in EBC patients treated with BCT.
背景/目的：本研究旨在探讨早期乳腺癌（EBC）保乳治疗（BCT）后淋巴细胞减少与同侧乳腺肿瘤复发（IBTR）之间的关联。
患者与方法
我们检查了216例接受部分乳房切除术后放疗（RT）的EBC患者，这些患者均未接受化疗。收集每位患者放疗后两年内的绝对淋巴细胞计数（ALC）：治疗前ALC、3 - 5个月时的ALC（ALC1）、9 - 11个月时的ALC、15 - 17个月时的ALC以及21 - 23个月时的ALC。
结果
102例ALC1≤1479细胞/μl（定义为淋巴细胞减少）的患者10年IBTR率显著高于102例ALC1>1479细胞/μl的患者（16.2%对1%，p = 0.0034）。多因素分析显示，年龄、手术切缘、人表皮生长因子受体和淋巴细胞减少是IBTR的显著预测因素。
结论
淋巴细胞减少是接受BCT治疗的EBC患者发生IBTR的潜在预测因素。
Zotero 插件